0.6885
5.11%
+0.0335
After Hours:
.699
0.0105
+1.53%
Aligos Therapeutics Inc stock is currently priced at $0.6885, with a 24-hour trading volume of 884.25K.
It has seen a +5.11% increased in the last 24 hours and a -12.52% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.6695 pivot point. If it approaches the $0.7157 resistance level, significant changes may occur.
Previous Close:
$0.655
Open:
$0.66
24h Volume:
884.25K
Market Cap:
$53.78M
Revenue:
$15.53M
Net Income/Loss:
$-87.68M
P/E Ratio:
-0.3605
EPS:
-1.91
Net Cash Flow:
$-79.02M
1W Performance:
-5.72%
1M Performance:
-12.52%
6M Performance:
+0.36%
1Y Performance:
-42.14%
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Name
Aligos Therapeutics Inc
Sector
Industry
Phone
800 466 6059
Address
One Corporate Drive, 2nd Floor, South San Francisco
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-06-23 | Upgrade | Jefferies | Hold → Buy |
Jan-06-23 | Upgrade | Piper Sandler | Neutral → Overweight |
Mar-23-22 | Downgrade | Piper Sandler | Overweight → Neutral |
Jan-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
Jan-06-22 | Downgrade | Jefferies | Buy → Hold |
Sep-09-21 | Initiated | SVB Leerink | Outperform |
May-17-21 | Resumed | Piper Sandler | Overweight |
Nov-10-20 | Initiated | Cantor Fitzgerald | Overweight |
Nov-10-20 | Initiated | JP Morgan | Overweight |
Nov-10-20 | Initiated | Jefferies | Buy |
Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Aligos Therapeutics Inc Stock (ALGS) Latest News
Piper Sandler maintains target on Aligos Therapeutics shares, says its a 'hidden gem' By Investing.com - Investing.com
Investing.com
After Plunging -13.71% in 4 Weeks, Here's Why the Trend Might Reverse for Aligos Therapeutics (ALGS)
Zacks Investment Research
Aligos Therapeutics Announces Chief Medical Officer Resignation - TipRanks.com - TipRanks
TipRanks
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 27.6% in April - MarketBeat
MarketBeat
Q2 2024 EPS Estimates for Aligos Therapeutics, Inc. (NASDAQ:ALGS) Lifted by Leerink Partnrs - Defense World
Defense World
The past year for Aligos Therapeutics (NASDAQ:ALGS) investors has not been profitable - Yahoo Movies Canada
Yahoo Movies Canada
Aligos Therapeutics Inc Stock (ALGS) Financials Data
Aligos Therapeutics Inc (ALGS) Revenue 2024
ALGS reported a revenue (TTM) of $15.53 million for the quarter ending December 31, 2023, a +11.66% rise year-over-year.
Aligos Therapeutics Inc (ALGS) Net Income 2024
ALGS net income (TTM) was -$87.68 million for the quarter ending December 31, 2023, a +8.71% increase year-over-year.
Aligos Therapeutics Inc (ALGS) Cash Flow 2024
ALGS recorded a free cash flow (TTM) of -$79.02 million for the quarter ending December 31, 2023, a +1.64% increase year-over-year.
Aligos Therapeutics Inc (ALGS) Earnings per Share 2024
ALGS earnings per share (TTM) was -$1.7414 for the quarter ending December 31, 2023, a +22.95% growth year-over-year.
About Aligos Therapeutics Inc
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Cap:
|
Volume (24h):